These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36583943)

  • 21. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recent development of selective cyclooxygenase-2 inhibitors].
    Kawai S
    Nihon Rinsho; 2002 Dec; 60(12):2370-7. PubMed ID: 12510364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
    Everts B; Währborg P; Hedner T
    Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs.
    Hayashi S; Ueno N; Murase A; Takada J
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):846-67. PubMed ID: 24517373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
    Fiorucci S; Meli R; Bucci M; Cirino G
    Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene.
    Baek SJ; Wilson LC; Lee CH; Eling TE
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1126-31. PubMed ID: 12023546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The unmet anti-inflammatory needs in orthopedics.
    Trippel SB
    Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):3-7. PubMed ID: 10193996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity.
    Carbone LD; Tylavsky FA; Cauley JA; Harris TB; Lang TF; Bauer DC; Barrow KD; Kritchevsky SB
    J Bone Miner Res; 2003 Oct; 18(10):1795-802. PubMed ID: 14584890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
    Pairet M; Engelhardt G
    Fundam Clin Pharmacol; 1996; 10(1):1-17. PubMed ID: 8900495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
    Tada Y; Nagasawa K
    Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting inhibition of COX-2: a review of patents, 2002-2006.
    da Cunha EF; Ramalho TC; Josa D; Caetano MS; de Souza TC
    Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):108-23. PubMed ID: 19075973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nimesulide analogues: From anti-inflammatory to antitumor agents.
    Catarro M; Serrano JL; Ramos SS; Silvestre S; Almeida P
    Bioorg Chem; 2019 Jul; 88():102966. PubMed ID: 31075744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes.
    Kato M; Nishida S; Kitasato H; Sakata N; Kawai S
    J Pharm Pharmacol; 2001 Dec; 53(12):1679-85. PubMed ID: 11804398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic pharmacological approach to the characterization of NSAIDs.
    Lora M; Denault JB; Leduc R; de Brum-Fernandes AJ
    Prostaglandins Leukot Essent Fatty Acids; 1998 Jul; 59(1):55-62. PubMed ID: 9758208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antirheumatic agents: Fenoprofen calcium (Nalfon), naproxen (Naprosyn), and tolmetin sodium (Tolectin).
    Lewis JR
    JAMA; 1977 Mar; 237(12):1260-1. PubMed ID: 300118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.
    Vuolteenaho K; Moilanen T; Moilanen E
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):10-4. PubMed ID: 17973900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.